

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

ANNOUNCEMENT ON RESIGNATION AND APPOINTMENT OF EXECUTIVE OFFICERS

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. Resignation of Executive Officers

On 20 July 2023, the Board received the resignation letters of Ms. Niu Shengfang (牛胜芳) (“**Ms. Niu**”) and Mr. Wang Xin (王欣) (“**Mr. Wang**”), pursuant to which Ms. Niu and Mr. Wang respectively gave notice of their resignations as Deputy General Manager of the Company due to job assignment changes (the “**Resignations**”). Following the Resignations, Ms. Niu no longer holds any position in the Company and Mr. Wang will still be employed by the Company.

In accordance with the relevant provisions including the Company Law and the Articles of Association of the Company, the Resignations shall take effect from the date on which Ms. Niu's and Mr. Wang's respective resignation letter has been served on the Board.

The Company would like to express its sincere gratitude to Ms. Niu and Mr. Wang for their respective outstanding contribution to the development of the Company during their tenure as Deputy General Manager of the Company.

2. Appointment of Executive Officer

The Company had, on 21 July 2023, duly convened its 4th Board meeting for the financial year ending 31 December 2023 by means of telephone conference in accordance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and upon nomination and deliberation at a meeting of the Office of General Manager of the Company and review by the Nomination Committee of the Company, the Board approved the resolution relating to the proposed appointment of Mr. Ma Jian (马健) as Chief Financial Officer (CFO) of the Company (the “**Proposed Appointment**”).

Mr. Ma Jian (马健), born in November 1978, is a certified public accountant. He obtained a Master of Business Administration Degree from Tianjin University of Finance and Economics in December 2016. From December 1998 to March 2007, Mr. Ma served as a Staff Member of the Finance Department of Tianjin Hebei Pharmaceutical Factory (天津市河北制药厂), a Staff Member of the Finance Department of Tianjin Taihe Pharmaceutical Co., Ltd. (天津太河制药有限公司) (“**Tianjin Taihe**”) in succession and further promoted as Head of the Finance Department of Tianjin Taihe. From March 2007 to June 2016, he successively served as Deputy Chief Staff Member, Deputy Head of the Finance Department, and Deputy Head of the Audit Department of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“**TPH**”). From June 2016

to July 2023, Mr. Ma successively held the posts of General Manager of Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) and Director of the Fund Management Center of TPH.

Based on the nomination and deliberation at a meeting of the Office of General Manager of the Company and the review by the Nomination Committee of the Company, the independent Directors of the Company for the time being have reviewed the matters with respect to the proposed appointment of Mr. Ma Jian as Chief Financial Officer (CFO) of the Company and have reviewed Mr. Ma's curriculum vitae and agreed with the Proposed Appointment

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
21 July 2023